First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Authors
Category Primary study
JournalBLOOD
Year 2020
This article has no abstract
Epistemonikos ID: 190551168d518aa99cafbb482827dd3d7b26a481
First added on: Feb 12, 2025